Breaking News Instant updates and real-time market news.

RVNC

Revance

$24.86

0.91 (3.80%)

04:55
10/17/18
10/17
04:55
10/17/18
04:55

Revance management to meet with Needham

Meetings to be held in the Midwest October 16-17 hosted by Needham.

  • 17

    Oct

  • 27

    Nov

RVNC Revance
$24.86

0.91 (3.80%)

09/17/18
09/17/18
DOWNGRADE

Market Perform
Revance downgraded to Market Perform after Allergan data at JMP Securities
As previously reported, JMP Securities analyst Donald Ellis downgraded Revance (RVNC) to Market Perform from Outperform after Allergan (AGN) released Botox study data that he said suggests that the longer duration of activity of Revance's RT002 may be partially or primarily due to a "dose" effect. While Ellis doesn't see Allergan conducting the trials needed for an FDA label change, he does think the data will be extensively shared at medical meetings and sees it minimizing the benefit of extended duration claims for RT002 versus Botox.
09/17/18
09/17/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Visa (V) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst James Schneider citing recent share out-performance. 2. Hormel Foods (HRL) downgraded to Market Perform from Outperform at BMO Capital with analyst Kenneth Zaslow citing valuation. 3. Costco (COST) downgraded to Equal Weight from Overweight at Barclays with analyst Karen Short citing valuation. 4. LyondellBasell (LYB) downgraded to Neutral from Buy at Citi with analyst P.J. Juvekar saying the current rise in ethane is likely to persist until Q2 of 2019. 5. Revance (RVNC) downgraded to Market Perform from Outperform at JMP Securities with analyst Donald Ellis citing Botox study data released by Allergan (AGN). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/18
CANT
09/18/18
NO CHANGE
Target $35
CANT
Overweight
Evolus selloff yesterday not based on fundamentals, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen sees no fundamental reason for the 12% pullback yesterday in shares of Evolus (EOLS). The stock weakness was partly attributed to the "upbeat and well-attended" investor day held by competitor Allergan (AGN) last Friday, Chen tells investors in a research note. The analyst points out that shares of Revance (RVNC), which also competes with Allergan in the botulinum toxin space, dropped yesterday as well. Chen believes Allergan's investor day renewed concerns that the company is and will remain the leading botulinum toxin/aesthetics player in the space. However, this is nothing new and is already priced into Evolus' valuation, Chen contends. The analyst continues to expect the company's launch of DWP-450 in spring 2019 to exceed "modest expectations." She keeps an Overweight rating on the shares with a $35 price target.
09/27/18
MZHO
09/27/18
NO CHANGE
Target $48
MZHO
Buy
Revance selloff on Allergan data a buying opportunity, says Mizuho
Mizuho analyst Difei Yang says that while Allergan's (AGN) new data from a Phase 1b trial of higher dose Botox in moderate-to-severe glabellar lines showed better duration relative to the standard dose Botox, Revance Therapeutics (RVNC) remains best positioned to address the long-duration botulinum toxin products market. The analyst believes the weakness in Revance shares during 2018 has created buying opportunities. The analyst reiterates a Buy rating on the stock with a $48 price target.

TODAY'S FREE FLY STORIES

KNX

Knight-Swift

$34.96

0.73 (2.13%)

12:05
02/20/19
02/20
12:05
02/20/19
12:05
Options
Knight Transportation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

12:05
02/20/19
02/20
12:05
02/20/19
12:05
General news
U.S. corporate bond update: the calendar remains active. »

U.S. corporate bond…

DNLI

Denali Therapeutics

$21.44

-0.16 (-0.74%)

12:03
02/20/19
02/20
12:03
02/20/19
12:03
Hot Stocks
Denali granted orphan status for mucopolysaccharidosis treatment »

The FDA granted Denali…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDY

Dr. Reddy's

$35.97

-0.45 (-1.24%)

12:03
02/20/19
02/20
12:03
02/20/19
12:03
Hot Stocks
Dr. Reddy's announces re-launch of buprenorphine, naloxone sublingual film »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

HSY

Hershey

$109.86

0.165 (0.15%)

12:01
02/20/19
02/20
12:01
02/20/19
12:01
Earnings
Hershey backs FY19 adjusted EPS growth view of 5%-7%, consensus $5.64 »

Backs FY19 net sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

QTT

Qutoutiao

$12.66

0.25 (2.01%)

12:01
02/20/19
02/20
12:01
02/20/19
12:01
Downgrade
Qutoutiao rating change  »

Qutoutiao downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

BHC

Bausch Health

$23.23

-1.94 (-7.71%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Bausch Health falls -7.7% »

Bausch Health is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 12

    Mar

IDT

IDT Corp

$6.48

-0.68 (-9.50%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
IDT Corp falls -9.1% »

IDT Corp is down -9.1%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.62

-1.32 (-16.62%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Owens & Minor falls -16.6% »

Owens & Minor is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

I

Intelsat

$24.38

2.755 (12.74%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Intelsat rises 12.8% »

Intelsat is up 12.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 11

    Mar

  • 11

    Mar

QUAD

Quad/Graphics

$16.58

2.04 (14.03%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Quad/Graphics rises 14.4% »

Quad/Graphics is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

LKSD

LSC Communications

$9.47

1.18 (14.23%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
LSC Communications rises 14.6% »

LSC Communications is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLNE

Clean Energy

$2.23

0.24 (12.06%)

11:58
02/20/19
02/20
11:58
02/20/19
11:58
Hot Stocks
Clean Energy jumps 12% after seeing demand increases for RNG from refuse sector »

Clean Energy Fuels,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

  • 12

    Mar

TKC

Turkcell

$6.97

0.06 (0.87%)

11:56
02/20/19
02/20
11:56
02/20/19
11:56
Hot Stocks
Breaking Hot Stocks news story on Turkcell 

Turkcell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 19

    Mar

DDAIF

Daimler AG

$0.00

(0.00%)

11:48
02/20/19
02/20
11:48
02/20/19
11:48
Periodicals
German prosecutors launch new probe into Daimler, Reuters reports »

Prosecutors in Germany…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

IQ

iQIYI

$22.76

0.43 (1.93%)

11:45
02/20/19
02/20
11:45
02/20/19
11:45
Options
iQiyi call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 20

    Mar

11:45
02/20/19
02/20
11:45
02/20/19
11:45
General news
Treasury's $18 B 2-year FRN reopening was a little soft »

Treasury's $18 B…

11:41
02/20/19
02/20
11:41
02/20/19
11:41
Conference/Events
UBS services analyst to hold an analyst/industry conference call »

Services Analyst Geiger,…

DVN

Devon Energy

$31.18

2.87 (10.14%)

11:41
02/20/19
02/20
11:41
02/20/19
11:41
Hot Stocks
Devon Energy sees FY19 total production 294-309 MBoe/d »

Sees FY19 oil production…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 27

    Feb

  • 28

    Feb

  • 22

    May

WIX

Wix.com

$110.04

-15.66 (-12.46%)

11:38
02/20/19
02/20
11:38
02/20/19
11:38
Recommendations
Wix.com analyst commentary  »

Wix.com strategy change…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 18

    Mar

11:35
02/20/19
02/20
11:35
02/20/19
11:35
General news
2-Yr FRN Note Auction Bid/Cover data reported »

2-Yr FRN Note Auction…

11:35
02/20/19
02/20
11:35
02/20/19
11:35
General news
2-Yr FRN Note Auction Total Amount data reported »

2-Yr FRN Note Auction…

DATA

Tableau

$128.02

1.08 (0.85%)

11:30
02/20/19
02/20
11:30
02/20/19
11:30
Options
Size time spread in Tableau Software paints a bullish picture »

Size time spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 06

    Mar

  • 07

    Mar

MO

Altria Group

$50.35

1.41 (2.88%)

11:26
02/20/19
02/20
11:26
02/20/19
11:26
Hot Stocks
Altria Group backs long-term adjusted EPS growth at 7%-9% annual rate »

In comments being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

11:25
02/20/19
02/20
11:25
02/20/19
11:25
General news
Treasury Action: Treasuries have given up some ground »

Treasury Action:…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.